Ascentage Pharma Group International (NASDAQ:AAPG) Stock Falls 6.6% – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) dropped 6.6% on Wednesday. The company traded as low as $14.85 and last traded at $15.03. 4,078 shares were traded during mid-day trading, a decline of 40% from the average session volume of 6,815 shares. The stock had previously closed at $16.09.

Analysts Set New Price Targets

AAPG has been the subject of a number of recent analyst reports. Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. BTIG Research restated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. Finally, B. Riley Financial started coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $46.43.

Ascentage Pharma Group International Stock Down 7.2%

The company has a 50 day moving average of $16.90 and a 200 day moving average of $19.46. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The business had revenue of $22.24 million during the quarter. Research analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that target mechanisms involved in programmed cell death. The company’s research is primarily directed toward cancer and other serious diseases in which regulating apoptosis may offer therapeutic benefits.

Its pipeline includes small-molecule drug candidates designed to inhibit proteins that help cancer cells survive. Key programs have included lisaftoclax (APG-2575), a BCL-2 inhibitor being investigated for hematologic malignancies, and APG-115, an MDM2-p53 inhibitor under evaluation in oncology indications.